[{"id":"5ca3f586-5d57-495c-9088-bac9d19c4782","acronym":"","url":"https://clinicaltrials.gov/study/NCT04826341","created_at":"2021-04-01T16:52:34.686Z","updated_at":"2025-02-25T13:40:26.267Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","source_id_and_acronym":"NCT04826341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-21"},{"id":"907c18db-1f38-4071-a1e3-b3af86377f13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05941520","created_at":"2023-07-12T16:10:13.477Z","updated_at":"2025-02-25T13:49:53.635Z","phase":"Phase 2","brief_title":"Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer","source_id_and_acronym":"NCT05941520","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2","pipe":" | ","alterations":" TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • acolbifene"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/23/2024","start_date":" 08/23/2024","primary_txt":" Primary completion: 08/23/2027","primary_completion_date":" 08/23/2027","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-02-21"},{"id":"f7e6df94-a121-41c2-ab20-30322990863a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05327010","created_at":"2022-04-14T12:53:52.597Z","updated_at":"2025-02-25T14:02:49.505Z","phase":"Phase 2","brief_title":"Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial","source_id_and_acronym":"NCT05327010","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 08/04/2025","primary_completion_date":" 08/04/2025","study_txt":" Completion: 08/04/2025","study_completion_date":" 08/04/2025","last_update_posted":"2025-02-19"},{"id":"87a9c1fe-92c6-4692-b3ba-4b7c76aefe9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02993068","created_at":"2021-01-18T14:43:23.226Z","updated_at":"2025-02-25T15:17:22.718Z","phase":"","brief_title":"Stand Up to Cancer: MAGENTA (Making Genetic Testing Accessible)","source_id_and_acronym":"NCT02993068","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["ER • PGR • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"],"overall_status":"Suspended","enrollment":" Enrollment 5200","initiation":"Initiation: 04/18/2017","start_date":" 04/18/2017","primary_txt":" Primary completion: 04/18/2026","primary_completion_date":" 04/18/2026","study_txt":" Completion: 04/18/2026","study_completion_date":" 04/18/2026","last_update_posted":"2025-02-12"},{"id":"d4a8f858-34d0-4450-b14d-4588fe783648","acronym":"","url":"https://clinicaltrials.gov/study/NCT05687110","created_at":"2023-01-18T15:59:52.715Z","updated_at":"2025-02-25T16:54:40.188Z","phase":"Phase 1","brief_title":"Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes","source_id_and_acronym":"NCT05687110","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 07/06/2023","start_date":" 07/06/2023","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-04"},{"id":"f228ffce-69d8-4696-a61e-6222a211f51d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05188508","created_at":"2022-01-12T14:53:32.609Z","updated_at":"2025-02-25T16:17:09.399Z","phase":"Phase 2","brief_title":"Pembrolizumab, Olaparib, and Temozolomide for People with Glioma","source_id_and_acronym":"NCT05188508","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type","tags":["EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 01/14/2022","start_date":" 01/14/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-03"},{"id":"73183b76-400c-42da-8908-2c1fc21637ec","acronym":"OPTIMUM","url":"https://clinicaltrials.gov/study/NCT05222971","created_at":"2022-02-05T18:29:24.003Z","updated_at":"2025-02-25T17:37:35.916Z","phase":"Phase 2","brief_title":"Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","source_id_and_acronym":"NCT05222971 - OPTIMUM","lead_sponsor":"Asan Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1","pipe":" | ","alterations":" ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-01-28"},{"id":"d934aafe-bd3e-4728-955c-fb7a4b80ce12","acronym":"HRPCa-II","url":"https://clinicaltrials.gov/study/NCT05333432","created_at":"2022-04-19T23:53:47.960Z","updated_at":"2025-02-25T17:37:45.989Z","phase":"","brief_title":"Evaluation of a Multimodal Strategy for Early Diagnosis of Men At High Genetic Risk of Prostate Cancer","source_id_and_acronym":"NCT05333432 - HRPCa-II","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • HOXB13","pipe":" | ","alterations":" PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • HOXB13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 880","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-01-28"},{"id":"04a57d4f-2959-452c-80a6-f0212d657b50","acronym":"","url":"https://clinicaltrials.gov/study/NCT04992013","created_at":"2021-08-05T13:53:09.751Z","updated_at":"2025-02-25T13:12:43.122Z","phase":"Phase 2","brief_title":"Niraparib in Tumors Metastatic to the CNS","source_id_and_acronym":"NCT04992013","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3","pipe":" | ","alterations":" HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/05/2022","start_date":" 04/05/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-12-12"},{"id":"75a29f57-27bd-4671-83cb-33821417c3f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03047135","created_at":"2021-01-18T15:00:24.273Z","updated_at":"2025-02-25T14:57:49.956Z","phase":"Phase 2","brief_title":"Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis","source_id_and_acronym":"NCT03047135","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A","pipe":" | ","alterations":" BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression","tags":["BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-07-03"},{"id":"a46c4912-0043-44e5-86b1-19d554f145ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT02760849","created_at":"2021-01-18T13:32:21.091Z","updated_at":"2024-07-02T16:34:37.526Z","phase":"","brief_title":"Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations","source_id_and_acronym":"NCT02760849","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" BARD1 mutation","tags":["BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BARD1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 374","initiation":"Initiation: 05/02/2016","start_date":" 05/02/2016","primary_txt":" Primary completion: 05/31/2041","primary_completion_date":" 05/31/2041","study_txt":" Completion: 05/31/2041","study_completion_date":" 05/31/2041","last_update_posted":"2024-06-06"},{"id":"b82d5afc-83e5-4037-9280-7d0e4dfd7f17","acronym":"NCI10217","url":"https://clinicaltrials.gov/study/NCT03842228","created_at":"2021-01-18T18:58:03.649Z","updated_at":"2024-07-02T16:35:02.758Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations","source_id_and_acronym":"NCT03842228 - NCI10217","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation","tags":["PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 11/21/2019","start_date":" 11/21/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-17"},{"id":"2f42b008-13bb-4250-8a51-d6031ca55a07","acronym":"MEDIOLA","url":"https://clinicaltrials.gov/study/NCT02734004","created_at":"2021-01-17T17:46:11.726Z","updated_at":"2024-07-02T16:35:04.420Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","source_id_and_acronym":"NCT02734004 - MEDIOLA","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • BRCA","pipe":" | ","alterations":" HER-2 negative • CDK12 mutation • BARD1 mutation","tags":["HER-2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • CDK12 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 264","initiation":"Initiation: 03/17/2016","start_date":" 03/17/2016","primary_txt":" Primary completion: 09/17/2021","primary_completion_date":" 09/17/2021","study_txt":" Completion: 09/17/2025","study_completion_date":" 09/17/2025","last_update_posted":"2024-05-10"},{"id":"64f232bf-1136-4191-96e8-05f7092ed952","acronym":"COMPRENDO","url":"https://clinicaltrials.gov/study/NCT05033756","created_at":"2021-09-05T16:55:47.679Z","updated_at":"2025-02-25T16:16:39.031Z","phase":"Phase 2","brief_title":"Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO","source_id_and_acronym":"NCT05033756 - COMPRENDO","lead_sponsor":"Institut fuer Frauengesundheit","biomarkers":" HER-2 • PGR • BRCA1 • BRCA2 • ATM • HRD • CHEK2 • RAD51C • RAD51D • BARD1 • XRCC2 • FANCC • SLX4","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • PGR positive • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["HER-2 • PGR • BRCA1 • BRCA2 • ATM • HRD • CHEK2 • RAD51C • RAD51D • BARD1 • XRCC2 • FANCC • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • PGR positive • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/30/2022","start_date":" 07/30/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-05-07"},{"id":"691969a6-dc3e-4580-99bb-0a9ff4f0cef1","acronym":"NIRADO","url":"https://clinicaltrials.gov/study/NCT04779151","created_at":"2021-03-03T13:57:08.218Z","updated_at":"2024-07-02T16:35:12.913Z","phase":"Phase 2","brief_title":"Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab","source_id_and_acronym":"NCT04779151 - NIRADO","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD","tags":["HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Suspended","enrollment":" Enrollment 51","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-03-26"},{"id":"e9a0c2de-92c2-4b8a-8b7f-5e473ce5f549","acronym":"ARIANES","url":"https://clinicaltrials.gov/study/NCT04276376","created_at":"2023-01-23T18:00:08.144Z","updated_at":"2024-07-02T16:35:12.843Z","phase":"Phase 2","brief_title":"Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors","source_id_and_acronym":"NCT04276376 - ARIANES","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • IL2 • RAD51D • BARD1 • NBN • RAD54L • DRD","pipe":" | ","alterations":" DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD","tags":["BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • IL2 • RAD51D • BARD1 • NBN • RAD54L • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Rubraca (rucaparib)"],"overall_status":"Suspended","enrollment":" Enrollment 130","initiation":"Initiation: 04/12/2019","start_date":" 04/12/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-03-26"},{"id":"ac71a659-88ba-460b-8829-91700d494013","acronym":"ORCHID","url":"https://clinicaltrials.gov/study/NCT03786796","created_at":"2021-01-18T18:43:55.909Z","updated_at":"2025-02-25T15:08:13.487Z","phase":"Phase 2","brief_title":"Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations","source_id_and_acronym":"NCT03786796 - ORCHID","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRCA1 • BRCA2 • BAP1 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • BAP1 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/03/2019","start_date":" 06/03/2019","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-03-05"},{"id":"10d0956a-4ec0-46e8-936a-8b03707ecfe5","acronym":"NEO","url":"https://clinicaltrials.gov/study/NCT02489006","created_at":"2021-01-18T11:59:49.235Z","updated_at":"2025-02-25T15:06:39.652Z","phase":"Phase 2","brief_title":"A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer","source_id_and_acronym":"NCT02489006 - NEO","lead_sponsor":"University Health Network, Toronto","biomarkers":" BRCA1 • BRCA2 • PALB2 • RAD51B • BRIP1 • RAD51C • PARP1 • RAD51D • BARD1 • PPM1D • FANCM","pipe":" | ","alterations":" PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • PALB2 • RAD51B • BRIP1 • RAD51C • PARP1 • RAD51D • BARD1 • PPM1D • FANCM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 07/19/2016","start_date":" 07/19/2016","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-17"},{"id":"be84ddd3-f2ce-46d3-ae9d-39c0fd0d285e","acronym":"DIDO","url":"https://clinicaltrials.gov/study/NCT04983745","created_at":"2021-07-30T17:55:02.511Z","updated_at":"2024-07-02T16:35:25.580Z","phase":"Phase 2","brief_title":"Niraparib and Dostarlimab in HRD Solid Tumors","source_id_and_acronym":"NCT04983745 - DIDO","lead_sponsor":"West Cancer Center","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A • FANCI","pipe":" | ","alterations":" BRCA1 mutation • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • HRD + BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A • FANCI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • HRD + BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/29/2021","start_date":" 11/29/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-12-21"},{"id":"2f53be06-79ab-4bcb-95d3-0cca269af9ef","acronym":"NCI-2021-12582","url":"https://clinicaltrials.gov/study/NCT05174455","created_at":"2021-12-30T14:55:55.326Z","updated_at":"2024-07-02T16:35:36.720Z","phase":"Phase 2","brief_title":"Niraparib for the Treatment of Leiomyosarcoma","source_id_and_acronym":"NCT05174455 - NCI-2021-12582","lead_sponsor":"David Liebner, MD","biomarkers":" BRCA1 • BRCA2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" BRCA1 mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-18"},{"id":"94c45794-3c7a-4a80-9968-91c364190829","acronym":"","url":"https://clinicaltrials.gov/study/NCT03207347","created_at":"2021-01-18T15:48:36.731Z","updated_at":"2025-02-25T13:12:22.396Z","phase":"Phase 2","brief_title":"A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)","source_id_and_acronym":"NCT03207347","lead_sponsor":"University of Florida","biomarkers":" PTEN • IDH1 • IDH2 • ARID1A • BAP1 • CDK4 • CHEK2 • RAD51 • BRIP1 • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • CDK2 • WRN • RAD52 • BACH1 • FANCG • PRKDC • RPA1 • ABRAXAS1 • FEN1 • SLX4","pipe":" | ","alterations":" BARD1 mutation","tags":["PTEN • IDH1 • IDH2 • ARID1A • BAP1 • CDK4 • CHEK2 • RAD51 • BRIP1 • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • CDK2 • WRN • RAD52 • BACH1 • FANCG • PRKDC • RPA1 • ABRAXAS1 • FEN1 • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 08/30/2022","study_completion_date":" 08/30/2022","last_update_posted":"2023-09-15"},{"id":"12b373a9-f27e-4aa8-b2c5-2cb259826f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03718091","created_at":"2021-01-18T18:13:18.198Z","updated_at":"2024-07-02T16:35:43.598Z","phase":"Phase 2","brief_title":"M6620 (VX-970) in Selected Solid Tumors","source_id_and_acronym":"NCT03718091","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation","tags":["BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 07/08/2020","study_completion_date":" 07/08/2020","last_update_posted":"2023-07-07"},{"id":"c66f765b-84b8-4be7-b6e5-f176047b0b9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04633902","created_at":"2021-01-19T20:37:04.111Z","updated_at":"2024-07-02T16:35:59.576Z","phase":"Phase 2","brief_title":"Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation","source_id_and_acronym":"NCT04633902","lead_sponsor":"California Pacific Medical Center Research Institute","biomarkers":" BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • ARID2 • BARD1 • FANCD2 • RAD54B","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRAF mutation • BRAF V600 • ATM mutation • ARID1A mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD50 mutation • BARD1 mutation","tags":["BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • ARID2 • BARD1 • FANCD2 • RAD54B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRAF mutation • BRAF V600 • ATM mutation • ARID1A mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD50 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/03/2021","start_date":" 03/03/2021","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-12-06"},{"id":"194b16b8-2e75-4a35-9c4d-d18efa63c817","acronym":"PROact","url":"https://clinicaltrials.gov/study/NCT05167175","created_at":"2021-12-22T19:15:14.382Z","updated_at":"2025-02-25T15:00:10.570Z","phase":"Phase 2","brief_title":"The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation","source_id_and_acronym":"NCT05167175 - PROact","lead_sponsor":"Hongqian Guo","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL","pipe":" | ","alterations":" PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • abiraterone acetate • prednisone"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-10-25"}]